Pure Global AI
NCT06010680Recruiting

A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers

Phase I Clinical Trial of Substance Balance of [14C]SHR2554 in Healthy Chinese Subjects
Jiangsu HengRui Medicine Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Lymphoma
Drug/Device/Intervention
[14C]SHR2554
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jiangsu HengRui Medicine Co., Ltd.
Location
Suzhou, China
Timeline & enrollment
Phase
Phase 1
Start date
Oct 07, 2023
End date
Dec 03, 2023
Enrollment
8 participants
Primary outcome

Cumulative recovery and recovery rate of total radioactive substance in urine and feces,Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC),Percentage of parent drug and its metabolites in urine and feces as a percentage of administered dose (%Dose),Radioactivity Tmax,Radioactivity Cmax,Radioactivity AUC,Radioactivity t1/2,Radioactivity CL/F,Radioactivity Vz/F,1Total radioactivity ratio for blood/plasma

Summary

Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Male Volunteers.

ICD-10 classifications
Hodgkin lymphomaFollicular lymphomaNon-Hodgkin lymphoma, unspecifiedFollicular lymphoma, unspecifiedHodgkin lymphoma, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06010680
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06010680 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jiangsu HengRui Medicine Co., Ltd. and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 8 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.